Provenance Wealth Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Provenance Wealth Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-328	Closed	-$26.6K	–	552
2025 Q1	$26.6K	Sell	328 -2,100	-86%	-$188K	﹤0.01%	258
2024 Q4	$219K	Hold	2,428	–	–	0.03%	140
2024 Q3	$240K	Hold	2,428	–	–	0.03%	142
2024 Q2	$225K	Sell	2,428 -226	-9%	-$20.3K	0.03%	132
2024 Q1	$252K	Hold	2,654	–	–	0.04%	129
2023 Q4	$237K	Buy	2,654 +100	+4%	+$7.43K	0.03%	119
2023 Q3	$186K	Buy	+2,554	New	+$204K	0.03%	120

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Provenance Wealth Advisors's XBI Position: Q2 2025 in Review

Provenance Wealth Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2025, closing a stake of 328 shares — an estimated $26.6K sold.

Provenance Wealth Advisors first reported a position in XBI in Q3 2023 and held it in 7 quarters. The position peaked at $252K in Q1 2024. 625 funds tracked by Wall St. Rank hold XBI as of Q2 2025.

Provenance Wealth Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2025 after selling out during the quarter.
Provenance Wealth Advisors sold 328 State Street SPDR S&P Biotech ETF shares in Q2 2025, an estimated $26.6K.
Provenance Wealth Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q3 2023 and held it in 7 quarters.
Provenance Wealth Advisors's State Street SPDR S&P Biotech ETF position peaked at $252K in Q1 2024.
625 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2025.

Based on Provenance Wealth Advisors's 13F filing for Q2 2025, filed 15 Aug 2025.